Clinical trial recruitment is often measured by how many prospective participants enter the funnel. But high lead volume does not necessarily translate into enrollment. Clinical trial referral quality depends on whether prospective participants reach investigative sites with the information, preliminary eligibility checks, medical records, and expectations needed for the site to act efficiently.

Research on clinical trial recruitment shows why this distinction matters. Screening is frequently one of the most time- and labor-intensive parts of recruitment, and a large volume of apparently interested participants can narrow considerably after secondary screening and medical record review.

For sponsors, CROs, and study teams, the goal should therefore be more than generating leads. A stronger recruitment model moves appropriate participants through a structured qualification process before referral, while preserving the investigative site’s responsibility for final eligibility and enrollment decisions. Secondary screening, medical record retrieval, eligibility checks, clear referral documentation, and timely handoffs can help sites spend more of their limited time evaluating participants who have a realistic opportunity to enroll. FDA and ICH guidance also reinforce the importance of well-designed eligibility criteria, documented pretrial screening processes, reliable source information, and trial processes proportionate to activities that matter most to trial quality.

The Problem With Optimizing Recruitment for Volume

Clinical trial recruitment begins with reach. Digital advertising, physician referrals, advocacy outreach, databases, study websites, and other channels can introduce a study to large numbers of potential participants. But the number of responses generated at the top of the funnel says little about how much usable enrollment opportunity ultimately reaches a site.

A real-world example comes from the PISCES III stroke trial, which used a patient-facing portal followed by centralized phone screening and medical record review. Of 5,446 people who completed first-tier screening, 4,290 were disqualified at that stage and 1,156 were referred for further consideration. Among subsequent referrals, 24 percent could not be contacted, another 9 percent declined after learning more about the study, and 41 percent of those completing a phone-based functional assessment failed that portion of screening. Later, medical records were requested for 224 prospective participants. Records were received for 158, and 72 of those prospective participants failed during medical record review.

That experience illustrates an important distinction for study teams: activity is not the same as readiness.

Sending every person who clears a basic web screener directly to a site can simply relocate the screening burden. Site coordinators may then spend time making repeated contact attempts, reconfirming information already collected, searching for medical history, determining whether key inclusion or exclusion criteria can be verified, and explaining study requirements to people who may not have understood what participation involves.

That burden is measurable. In a mixed-methods study across 10 university hospitals, researchers found that identifying and screening prospective participants involved clinicians, investigators, study nurses, and other staff. Forty-six percent of interviewees reported that identifying suitable patients interfered with routine care, and screening against eligibility criteria was identified as the most time- and labor-intensive recruitment step. Data retrieval and other coordination activities were also reported as time-consuming.

For recruitment programs, the implication is straightforward: increasing traffic without improving qualification can increase workload faster than enrollment.

What Makes a Referral Site-Ready

Improving clinical trial referral quality does not mean replacing site screening or making a final determination of eligibility before the participant reaches the investigator. The investigative site retains its responsibilities for trial conduct, participant protection, informed consent, and eligibility decisions. ICH E6(R3) treats recruitment and pretrial screening documentation, source records, and participant medical history as important elements of trial conduct and recordkeeping.

Instead, quality means removing avoidable uncertainty before the handoff.

Secondary screening adds clinical context

A first-level pre-screener is useful for objective questions such as age, location, diagnosis, or basic medical history. More complex protocols often require a second layer.

Secondary screening can clarify ambiguous answers, verify that the individual understood the question, assess criteria that are difficult to express in a simple online form, explain participation requirements, and determine what information still needs verification. The PISCES III model used this type of tiered process, moving from initial screening to telephone assessment and then to medical record review before site evaluation.

That progression is especially important when eligibility criteria depend on disease severity, treatment history, diagnostic findings, concomitant conditions, laboratory values, imaging, or other information a prospective participant may not accurately recall.

Medical records can answer questions self-report cannot

Medical record retrieval is another important quality step when protocol criteria depend on documented clinical history. FDA guidance recognizes EHRs as sources of health information that can support clinical investigations, while ICH E6(R3) identifies medical and health records as source records relevant to trial data and participant history. Appropriate authorization, privacy protections, and study-specific procedures still apply.

In the PISCES III trial, records were organized for review of emergency department notes, history and physical documentation, neurological consultations, discharge summaries, and imaging reports. That review was used to verify clinical characteristics that could not be confirmed reliably from patient report alone.

The purpose is not to create additional bureaucracy. It is to answer critical eligibility questions before a participant and site invest time in a visit that may end in a predictable screen failure.

A Practical Clinical Trial Referral Quality Workflow

The most effective workflow connects recruitment, qualification, records, and site handoff rather than treating them as separate activities. CTTI recommends planning recruitment around realistic eligibility criteria, trial feasibility, participant and provider barriers, and site burden before recruitment problems appear downstream.

Consistency matters. Screening questions, definitions, escalation rules, and handoff criteria should be aligned across recruitment teams and sites. In PISCES III, investigators found discrepancies between centralized and site-level assessments; retraining and use of a unified screening approach improved agreement and reduced the final site screen-failure rate.

A strong process should also avoid unnecessary exclusions. FDA’s December 2025 guidance recommends examining eligibility criteria for scientific and safety justification and eliminating or modifying criteria that unnecessarily restrict participation. Better referral quality should mean applying the protocol accurately, not making the recruitment funnel artificially narrow.

Measuring Clinical Trial Referral Quality

Lead count can remain a useful operational metric, but it should sit alongside measures that indicate what happens after a referral reaches the qualification process.

Three KPIs are particularly useful:

These metrics should be interpreted together. A very high qualified-referral rate is not automatically desirable if screening rules are excluding potentially eligible people too aggressively. Likewise, a low site conversion rate may reflect referral quality, site capacity, handoff delays, patient contactability, or protocol-specific challenges. It should be emphasized that recruitment practices and eligibility criteria should support appropriate participation while protecting participants and maintaining the scientific objectives of the trial.

The most useful dashboards therefore pair conversion metrics with reason codes. Understanding why referrals stop moving, such as unreachable participant, participant declined, missing records, inclusion criterion not met, exclusion criterion met, site capacity, or scheduling barrier, turns recruitment reporting into an operational improvement tool.

Conclusion

More leads can create more opportunities, but they can also create more work. For complex clinical trials, clinical trial referral quality is what determines whether recruitment activity arrives at the site as a useful enrollment opportunity or another screening task.

A structured pathway that combines accurate referral intake, secondary screening, appropriate medical record retrieval, protocol-based eligibility checks, and a documented site handoff can reduce preventable screening work and help study teams identify the participants who merit site-level evaluation sooner. Evidence from centralized and technology-supported recruitment models shows that substantial filtering can occur after initial interest, including during phone screening and medical record review.

The objective is not to eliminate screen failures. Some uncertainty will remain until the investigative site completes formal screening. The better objective is to make each step add useful information, so that sites receive fewer avoidable false-positive referrals and can focus their time on the prospective participants most appropriate for further evaluation. That approach aligns with the broader GCP principle of concentrating trial processes on activities that are critical to participant protection, data reliability, and successful trial execution.